Duitse aandelen « Terug naar discussie overzicht

Bayer Jaardraadje 2024

304 Posts, Pagina: « 1 2 3 4 5 6 7 ... 12 13 14 15 16 » | Laatste
LL
0
(CercleFinance.com) - Stifel downgrades its Bayer shares from 'buy' to 'hold', with a target price reduced from E68 to E42, preferring to 'stay on the sidelines', despite some upside potential for the stock, following a review of options for the German group.

The broker considers that a separation from consumer healthcare 'can create value, but is no short-term solution for the stretched balance sheet', and believes that a separation from agrochemicals would destroy value.

In conclusion, Stifel sees further downside potential for the consensus over the coming months, and estimates that EBITDA could decline by 11% in 2024, following a fall of around 20% last year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
Strateeg
0
Ondanks dat Stifel het koersdoel reduceert krabbelt het toch weer op. We zijn trouwens nog lang niet bij Euro 42,--
Strateeg
0
Ze drukken hem helaas naar beneden met dank aan de voor mij onbekende analist Stifel.
Verdere berichten zijn positief
LL
1
Bayer: begins heart failure study
(CercleFinance.com) - Bayer announced on Thursday the start of a Phase II clinical trial to assess the efficacy of the AB-1002 gene therapy developed by its biotech subsidiary AskBio in the treatment of heart failure.

The German group reports that it has enrolled the first patients in this trial, which is expected to enroll between 90 and 150 people in all, and will be conducted over 52 weeks in the US and Europe.

Congestive heart failure occurs when the heart is unable to pump blood efficiently enough to meet the body's needs, notably to supply sufficient oxygen to the organs, and is characterised by a slowing of blood flow out of the heart.
Strateeg
0
Snovkov
1
Dit jaar meer duidelijkheid in rechtzaken, bezuinigingsronde en opsplitsingscenario.
% of 15 moet lukken
N audio
0
Theoretisch heb je zeker een punt in je bijdrage. Phase II studie is trouwens nog wel vroeg in het proces.
We gaan 't zien.
LL
1
BERLIN, Jan 15 (Reuters) - Germany's trade union IG BCE has pushed back against a possible split-up of drugmaker Bayer , which it says is envisaged by some shareholders, arguing such a move would endanger jobs in Germany.

"For us, it's about keeping Bayer together," Michael Vassiliadis, leader of the IG BCE trade union, said in Berlin.

A split-up would weaken individual company segments, making them more prone to takeovers, he said, adding that it was unclear whether the pharmaceuticals business or the company's headquarters would stay in Germany in such an event.

Vassiliadis said CEO Bill Anderson's plans for a new management structure were currently being discussed. The trade union was not yet convinced of a reduction in middle management positions at Bayer, he said.

(Reporting by Matthias Inverardi and Patricia Weiß, Writing by Nette Nöstlinger, Editing by Christina Fincher)
LL
0
verklaring koersval:

Jan 18 (Reuters) - German drugmaker Bayer AG is leaning against breaking up the conglomerate, rejecting pleas from investors amid the company's ongoing struggle to recover from its purchase of Monsanto, Bloomberg News reported on Thursday, citing people familiar with the matter.
effegenoeg
1
quote:

LL schreef op 18 januari 2024 13:10:

verklaring koersval:

Jan 18 (Reuters) - German drugmaker Bayer AG is leaning against breaking up the conglomerate, rejecting pleas from investors amid the company's ongoing struggle to recover from its purchase of Monsanto, Bloomberg News reported on Thursday, citing people familiar with the matter.
Ik zie er ook niets in.
Bij opknippen krijg je van elk toch weer een stukkie terug.
Strateeg
0
Dank voor alle informatie. Misschien een beetje bijkopen. koers is nu 5 keer de winst.
304 Posts, Pagina: « 1 2 3 4 5 6 7 ... 12 13 14 15 16 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 913,25 -0,31 -0,03% 17 mei
AMX 953,09 -0,67 -0,07% 17 mei
ASCX 1.224,60 +5,98 +0,49% 17 mei
BEL 20 4.004,80 +9,70 +0,24% 17 mei
Germany40^ 18.716,50 -22,31 -0,12% 17 mei
US30^ 39.995,10 0,00 0,00% 17 mei
US500^ 5.302,48 0,00 0,00% 17 mei
Nasd100^ 18.540,20 0,00 0,00% 17 mei
Japan225^ 38.732,00 0,00 0,00% 17 mei
WTI 79,51 0,00 0,00% 17 mei
Brent 83,87 0,00 0,00% 17 mei
EUR/USD 1,0870 +0,0003 +0,03% 17 mei
BTC/USD 66.936,85 +1.450,00 +2,21% 05:35
Gold spot 2.415,21 0,00 0,00% 17 mei
#/^ Index indications calculated real time, zie disclaimer
BESTEL HIER UW TICKETS VOOR DE IEX BELEGGERSDAG > EEN DAG VOL INSPIRERENDE SPREKERS EN KOOPTIPS!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
UMG 28,740 +0,580 +2,06% 17 mei
ING 16,524 +0,298 +1,84% 17 mei
Philips Koninklijke 25,870 +0,460 +1,81% 17 mei
Dalers Laatst +/- % tijd
ADYEN NV 1.241,200 -41,000 -3,20% 17 mei
PROSUS 35,785 -0,840 -2,29% 17 mei
IMCD 139,400 -3,250 -2,28% 17 mei

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront